US FDA approves labeling changes to menopause hormone therapies

Feb 12 (Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved labeling changes to six menopause hormone therapies to remove references to risks of cardiovascular disease, breast cancer, and probable dementia. The FDA had initiated the removal of the strictest "black box" warnings in November in a move to boost access to these treatments long shunned by patients and